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Abstract: Although PTP4A3 has been shown to be a very important factor in promoting cancer 
progression, the role of its close family member PTP4A2 is still largely unknown. Recent reports 
have shown contradicting results on the role of PTP4A2 in breast cancer progression. Considering 
this, we aimed to investigate the prognostic value of PTP4A2 in five independent breast cancer data 
sets (minimum 198 patients per cohort, totaling 1,124 patients) in the Gene Expression Omnibus 
Database. We found that high expression of PTP4A2 was a favorable prognostic marker in all 
five independent breast cancer data sets, as well as in the combined cohort, with a hazard ratio of 
0.68 (95% confidence interval =0.56–0.83; P,0.001). Low PTP4A2 expression was associated 
with estrogen receptor-negative tumors and tumors with higher histological grading; furthermore, 
low expression was inversely correlated with the expression of genes involved in proliferation, 
including MKI67 and the MCM gene family encoding the minichromosome maintenance proteins. 
These findings suggest that PTP4A2 may play a role in breast cancer progression by dysregulating 
cell proliferation. PTP4A2 expression was positively correlated with ESR1, the gene encoding 
estrogen receptor-alpha, and inversely correlated with EGFR expression, suggesting that PTP4A2 
may be involved in these two important oncogenic pathways. Together, our results suggest that 
expression of PTP4A2 is a favorable prognostic marker in breast cancer.
Keywords: breast cancer, PTP4A2, survival, prognostic marker, overexpression, minichromo-
some maintenance proteins
Introduction
The protein tyrosine phosphatase (PTP) family consists of PRL-1, PRL-2, and PRL-3, 
which are encoded by the PTP4A1, PTP4A2, and PTP4A3 genes, respectively. Zeng 
et al1 were the first to identify PTP4A2 and PTP4A3, owing to their homology to 
PTP4A1; subsequently, the same group2 showed that PTP4A1 and PTP4A3 could both 
promote cell migration, invasion, and metastasis. Recently, the molecular mechanisms 
for PTP4A3-mediated cancer progression have been studied and revealed,3 with roles 
in the promotion of epithelial–mesenchymal transition,4 angiogenesis,5 cell cycle 
regulation,6 and autophagy7 having been discovered. Although overexpression of 
PTP4A3 has been consistently shown to promote cancer progression in multiple types 
of cancer, there are very few reports on the role of PTP4A2 in cancer progression.8
Overexpression of PTP4A2 was shown to promote breast tumor formation in 
a mouse model.9 However, two studies10,11 have shown that PTP4A2 was not dif-
ferentially expressed between normal, benign, and cancerous tissues of the breast, 
while two other recent publications12,13 demonstrated that increased expression of 
PTP4A2 was correlated with a favorable overall and disease-free survival. These 
contradictory findings on the role of PTP4A2 in breast cancer progression led us to 
investigate the prognostic significance of PTP4A2 gene expression in five publicly 
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available breast cancer data sets, each comprising at least 
198 patients. We have assessed the association between 
PTP4A2 expression and proliferation markers including 
MKI67 and the MCM gene family encoding the minichro-
mosome maintenance proteins, which were previously 
shown to confer prognostic significance in breast cancer 
patients.14
Materials and methods
Extraction of clinical and microarray 
gene expression data from breast cancer 
patient data sets
Five breast cancer patient data sets, GSE2034,15 GSE3494,16 
GSE7390,17 GSE11121,18 and GSE1227619 were identified 
in the Gene Expression Omnibus (GEO) database using the 
following inclusion criteria: data sets compiled using the 
HG-U133 microarray platform, comprising .180 patients, 
and for whom relapse or survival data were available. 
Microarray gene expression data were retrieved from the 
data matrices deposited in the GEO database by the origi-
nal authors. R scripting was used to extract the expression 
values from probe sets of genes of interest, and the clinical 
data from the data matrices was downloaded from GEO as 
previously described.20
Correlations of gene expression levels 
and clinical data
All statistical analyses were performed using SPSS19.0. The 
associations between expression level of PTP4A2 and clinical 
characteristics of the tumor, including estrogen receptor (ER) 
status and histological grade, and that between expression 
level of PTP4A2 and expression of MCM2-7 were tested 
by analysis of variance. The correlations between expres-
sion levels of PTP4A2 and MKI67, PTP4A2 and ESR1 (the 
gene encoding ER-alpha), and PTP4A2 and EGFR (gene 
encoding epidermal growth factor receptor) were tested 
by the Spearman’s rank test. Expression levels of PTP4A2 
were divided into high and low levels using lower quartile 
expression level as the cutoff point for survival analysis. For 
Kaplan–Meier survival analysis, results were compared by 
the Wilcoxon–Gehan test.
Identification of genes coexpressed  
with PTP4A2
Patients were stratified into two groups based on their 
expression levels of PTP4A2. The gene expression pat-
terns of patients in the PTP4A2-low subgroup and those in 
the PTP4A2-high subgroup were compared. Probe sets that 
were differentially expressed between these two subgroups 
were identified by the two-sample Welch’s t-test. This 
test was used to avoid the type I error that can arise due to 
unequal variances of the values of probe sets between sub-
groups. Briefly, a Welch’s t-test was applied to each probe set 
corresponding to a certain gene in the data matrix using our 
own Java application MyStats. P-values and the differential 
expression in fold changes for all the probe sets were gener-
ated as tab-delimited worksheets of Excel for further analysis. 
The genes were prioritized by ascending P-values.
Results
The association between PTP4A2 
expression level and survival in breast 
cancer patients
As shown in Figure 1, a low-level expression of PTP4A2 was 
consistently (and in four of the five cohorts, significantly) 
associated with a shorter survival time in the breast cancer 
data sets tested. In cohort GSE2034, patients whose tumors 
expressed PTP4A2 at a high level had a mean relapse-free 
survival time of 10.2 years, while those whose tumors 
expressed PTP4A2 at a low level had a mean relapse-free 
survival time of 8.4 years (Wilcoxon–Gehan test, P=0.006; 
Figure 1A). In cohort GSE3494, patients whose tumors 
expressed PTP4A2 at a high level had a mean disease-specific 
survival time of 10.7 years, while those whose tumors 
expressed PTP4A2 at a low level had a mean disease-specific 
survival time of 9.5 years (P=0.191; Figure 1B). In cohort 
GSE7390, patients whose tumors expressed PTP4A2 at a 
high level had a mean survival time of 19.7 years, while those 
whose tumors expressed PTP4A2 at a low level had a mean 
survival time of 15.7 years (P=0.001; Figure 1C). In cohort 
GSE11121, patients whose tumors expressed PTP4A2 at a 
high level had a mean distant metastasis-free survival time of 
15.7 years, while those whose tumors expressed PTP4A2 at 
a low level had a mean distant metastasis-free survival time 
of 11.9 years (P=0.006; Figure 1D). In cohort GSE12276, 
patients whose tumors expressed PTP4A2 at a high level had 
a mean survival time of 2.4 years, while those whose tumors 
expressed PTP4A2 at a low level had a mean survival time 
of 1.4 years (P,0.001; Figure 1E). Our results suggest that a 
low-level expression of PTP4A2 is associated with a shorter 
survival time in breast cancer patients.
The association between the expression 
of PTP4A2 and er status
ER is a key biomarker in breast cancer, its status being asso-
ciated with the efficacy of hormonal therapy. We analyzed 
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all three cohorts for which patient ER status was known to 
investigate whether PTP4A2 expression level varied between 
patients with ER-positive and those with ER-negative 
disease. In cohort GSE2034, the 77 ER-negative tumors had 
significantly lower level of expression of PTP4A2 compared 
to the 209 ER-positive tumors (P,0.001; Figure 2A). In 
cohort GSE3494, the 31 ER-negative tumors had signifi-
cantly lower level of expression of PTP4A2 compared to 
the 201 ER-positive tumors (P,0.001; Figure 2B). In cohort 
GSE7390, the 64 ER-negative tumors had significantly 
lower level of expression of PTP4A2 compared to the 134 
ER-positive tumors (P,0.001; Figure 2C). Because ER-
negative breast tumors are more aggressive and have a poorer 
prognosis,21 and considering that we have observed high 
PTP4A2 to be a favorable prognostic marker, it is unsurpris-
ing that low PTP4A2 correlates with ER-negative status.
Interestingly, ESR1 was identified as one of the 
genes being coexpressed with PTP4A2 in all the five 
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Figure 1 The association between PTP4A2 expression and patient survival.
Notes: Kaplan–Meier curves for PTP4A2 expression in (A) gse2034, (B) gse3494, (C) gse7390, (D) gse11121, and (E) gse12276 breast cancer data sets.
Abbreviation: PTP4A2, protein tyrosine phosphatase 4a2.
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breast cancer data sets. The expression levels of PTP4A2 
and ESR1 were significantly correlated in GSE2034 
(r=0.401, P,0.001; Figure 2D), GSE3494 (r=0.524, 
P,0.001; Figure 2E), GSE7390 (r=0.573, P,0.001; 
Figure 2F), GSE11121 (r=0.460, P,0.001; Figure 2G), 
and GSE12276 (r=0.566, P,0.001; Figure 2H) breast 
cancer data sets. Because ER-negative tumors had a lower 
expression of PTP4A2, while ESR1 and PTP4A2 expres-
sion was positively significantly correlated, our results 
suggest that ESR1 and PTP4A2 may be regulated in series 
or parallel in the same pathway.
The association between PTP4A2 
expression level and histological grade
Histological grade is another important prognostic factor in 
breast cancer.22 Here, we also investigated the association 
between the expression level of PTP4A2 and the histo-
logical grading of the tumors in the three cohorts for which 
tumor grade had been documented. As shown in Figure 3, 
PTP4A2 expression was significantly lower in grade 3 tumors 
compared to those tumors with lower grading in GSE3494 
(P=0.012; Figure 3A), GSE7390 (P,0.001; Figure 3B), and 
GSE11121 (P=0.009; Figure 3C), all the three breast cancer 
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Figure 2 The association between PTP4A2 expression and the er status and expression.
Notes: Box plots of PTP4A2 expression in tumors with different ER statuses in (A) gse2034, (B) gse3494, and (C) GSE7390 breast cancer data sets. Scatter plots for 
PTP4A2 expression against ESR1 expression in (A) gse2034, (B) gse3494, (C) gse7390, (D) gse2034, (E) gse3494, (F) gse7390, (G) gse11121, and (H) gse12276 
breast cancer data sets.
Abbreviations: ER, estrogen receptor; ESR1, the gene encoding estrogen receptor-alpha; PTP4A2, protein tyrosine phosphatase 4a2.
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data sets with histological grading available in GEO database. 
The results suggest that PTP4A2 expression is downregulated 
in breast tumor with increasing histological grading.
The association between PTP4A2 
expression and the expression 
of proliferation-related genes
Next, to further elucidate the role of PTP4A2 in breast cancer 
progression, we investigated whether PTP4A2 expression is cor-
related with the expression of proliferation-related genes. It has 
been previously shown that MKI67 is an important prognostic 
and predictive biomarker in breast cancer.23 In the present study, 
we investigated the correlation between the expression levels of 
PTP4A2 and MKI67. As shown in Figure 4, the expression level 
of PTP4A2 was inversely correlated with the expression level 
of MKI67 in breast cancer specimens in GSE2034 (r=-0.354, 
P,0.001; Figure 4A), GSE3494 (r=-0.208, P=0.001; Figure 
4B), GSE7390 (r=-0.434, P,0.001; Figure 4C), GSE11121 
(r=-0.321, P,0.001; Figure 4D), and GSE12276 (r=-0.271, 
P,0.001; Figure 4E) breast cancer data sets.
The MCM proteins play an important role in the regula-
tion of cell proliferation and the initiation of DNA synthesis,24 
and we have previously shown that members of the MCM 
gene family, when considered together, were a robust indica-
tor of poor prognosis in breast cancer.14 In the present study, 
we investigated the correlation between the expression level 
of PTP4A2 and MCM gene family overexpression in the five 
breast cancer cohorts. As shown in Figure 5, the expression 
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Figure 3 The association between PTP4A2 expression and histological grading.
Notes: Box plots of PTP4A2 expression in tumors with different histological grades in (A) gse3494, (B) gse7390, and (C) gse11121 breast cancer data sets.
Abbreviation: PTP4A2, protein tyrosine phosphatase 4a2.
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Figure 4 The correlations between PTP4A2 expression and MKI67 expression.
Notes: Scatter plots for PTP4A2 expression against MKI67 expression in (A) gse2034, (B) gse3494, (C) gse7390, (D) gse11121, and (E) gse12276 breast cancer data sets.
Abbreviations: MKI67, marker of proliferation Ki-67; PTP4A2, protein tyrosine phosphatase 4a2.
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Figure 5 The association between PTP4A2 expression and the number of overexpressed MCM genes.
Notes: Box plots of PTP4A2 expression in tumors with increasing number of overexpressed MCM genes in (A) gse2034, (B) gse3494, (C) gse7390, (D) gse11121, and 
(E) gse12276.
Abbreviations: MCM, minichromosome maintenance; PTP4A2, protein tyrosine phosphatase 4a2.
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level of PTP4A2 decreased as the number of MCM genes 
expressed at a high level increased in cohorts GSE2034 
(P,0.001; Figure 5A), GSE3494 (P=0.014; Figure 5B), 
GSE7390 (P,0.001; Figure 5C), GSE11121 (P,0.001; 
Figure 5D), and GSE12276 (P,0.001; Figure 5E).
The prognostic significance of PTP4A2 
in patients with different ER statuses 
or histological grading
Because PTP4A2 expression was shown to be associated 
with survival and ER status, we further investigated whether 
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Figure 6 The association between PTP4A2 expression and survival in patients stratified on clinicopathological parameters.
Notes: Kaplan–Meier curves for PTP4A2 expression in the combined breast cancer data set for (A) the entire combined cohort, (B) patients with er-negative tumors, 
(C) patients with er-positive tumors, (D) patients with grade 1 tumors, (E) patients with grade 2 tumors, and (F) patients with grade 3 tumors.
Abbreviations: ER, estrogen receptor; PTP4A2, protein tyrosine phosphatase 4a2.
the prognostic value of PTP4A2 is dependent on the ER 
status of the tumors. The five data sets were combined to 
increase the sample size and the statistical power to detect 
significant differences. In the combined data set, patients 
whose tumors expressed PTP4A2 at a low level had a mean 
survival time of 12.9 years, which was significantly shorter 
than those patients whose tumors expressed PTP4A2 at a high 
level, whose mean event-free survival time was 15.1 years 
(P,0.001; Figure 6A).
The prognostic significance of PTP4A2 was further 
analyzed in the 716 (out of 1,124) patients for whom the 
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ER status was known. In the 172 patients with ER-negative 
tumors, those patients whose tumors expressed PTP4A2 at a 
low level had a significantly shorter event-free survival time 
than those whose tumors expressed PTP4A2 at a high level 
(P=0.031; Figure 6B). Similarly, in the 544 patients with 
ER-positive status, those patients whose tumors expressed 
PTP4A2 at a low level had a significantly shorter event-free 
survival time compared to those whose tumors expressed 
PTP4A2 at a high level (P=0.033; Figure 6C).
The prognostic significance of PTP4A2 was also analyzed 
in the 630 patients for whom tumor histological grade was 
known. In the 121 and 169 patients with grade 1 and 3 tumors, 
respectively, the event-free survival time was not signifi-
cantly different between patients whose tumors expressed 
PTP4A2 at a high level and those whose tumors expressed 
PTP4A2 at a low level (Figure 6D and F). In the 340 patients 
with grade 2 tumors, those patients whose tumors expressed 
PTP4A2 at a low level had a significantly shorter event-free 
survival time compared to those whose tumors expressed 
PTP4A2 at a high level (P=0.004; Figure 6E).
The correlation between PTP4A2 
and EGFR expression
Considering that EGFR is known to regulate PTP4A3,25 
we aimed to determine whether PTP4A2 and EGFR are 
coexpressed in breast cancer. As shown in Figure 7, the 
expression level of PTP4A2 was inversely correlated with 
the expression level of EGFR in all five breast cancer data 
sets analyzed, including GSE2034 (r=-0.364, P,0.001; 
Figure 7A), GSE3494 (r=-0.475, P,0.001; Figure 7B), 
GSE7390 (r=-0.447, P,0.001; Figure 7C), GSE11121 
(r=-0.468, P,0.001; Figure 7D), and GSE12276 (r=-0.394, 
P,0.001; Figure 7E).
Discussion
In the present study, we have demonstrated that PTP4A2 
expression is a favorable prognostic marker for breast cancer 
patients. A low-level expression of PTP4A2 was associated 
with ER-negative tumor status, while PTP4A2 expression 
level was positively correlated with ESR1 expression level, 
suggesting that PTP4A2 may be regulated by the ER path-
way. However, the prognostic significance of PTP4A2 was 
independent of tumor ER status. In addition, we found that 
PTP4A2 expression level was significantly lower in breast 
cancers with high histological grade, and that PTP4A2 
expression was only significantly predictive of survival in 
patients with grade 2 tumors. On the other hand, PTP4A2 
expression was inversely correlated with that of proliferation-
associated genes, including MKI67 and MCM2–7. Finally, 
we have putatively identified EGFR as a gene coexpressed 
with PTP4A2 in all five breast cancer data sets, suggesting 
that PTP4A2 may be involved in the EGFR pathway.
The prognostic significance of PTP4A2 is controversial 
because some reports suggest that PTP4A2 promotes breast 
cancer progression,9 while others suggest that PTP4A2 plays 
an opposite role suppressing breast cancer progression.12,13 
Considering these contradicting reports, we tested the prog-
nostic significance of PTP4A2 in five large breast cancer data 
sets available in the GEO database. The results are highly 
consistent between these five breast cancer data sets, showing 
that a low-level expression of PTP4A2 mRNA was associated 
with a shorter event-free survival time, therefore suggesting 
that PTP4A2 expression is a favorable prognostic marker.
The regulation of PTP4A2 during breast cancer pro-
gression is largely unknown. In the present study, we have 
revealed two pathways that could potentially regulate 
PTP4A2. The first one is the ER pathway, wherein PTP4A2 
expression was significantly higher in ER-positive tumors 
than in ER-negative tumors, and its expression was positively 
correlated with that of ER-alpha gene (ESR1). On the other 
hand, PTP4A2 expression was inversely correlated with 
EGFR. Our results warrant further analysis to investigate in 
vitro whether PTP4A2 is downstream of these two important 
pathways.
The observation of an association between increased 
expression of PTP4A2 and decreased expression of pro-
liferation genes provides further insight into the possible 
mechanism for the role of PTP4A2 during cancer progres-
sion; alternatively, it is possible that PTP4A2 is a driver 
that inhibits proliferation of breast cancer cells, while it is 
also possible that downregulation of PTP4A2 is only a by-
product of the dysregulated proliferation in breast cancer. 
Nonetheless, this result was consistent with the observation 
that PTP4A2 expression is a favorable prognostic marker in 
breast cancer.
One limitation of our study is that, as protein expression 
data are not available in the tested cohorts, our study is limited 
to the analysis of mRNA levels of PTP4A2; investigation 
on PRL-2 protein expression in a breast cancer cohort is 
required to validate our results and confirm the prognostic 
significance of PTP4A2.
In conclusion, the prognostic significance of PTP4A2 
has been demonstrated with a high consistency. Because 
of the conflicting data presented previously, our study has 
provided convincing information that PTP4A2 expression is 
a favorable prognostic marker. Nevertheless, further inves-
tigations on how PTP4A2 is regulated and the molecular 
mechanisms driven by PTP4A2 in breast cancer progression 
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Figure 7 The correlations between PTP4A2 expression and EGFR expression.
Notes: Scatter plots for PTP4A2 expression against EGFR expression in (A) gse2034, (B) gse3494, (C) gse7390, (D) gse11121, and (E) gse12276 breast cancer data sets.
Abbreviations: EGFR, epidermal growth factor receptor; PTP4A2, protein tyrosine phosphatase 4a2.
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are required to fully elucidate the role of PTP4A2 in breast 
cancer progression.
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